Video

Dr. Scagliotti on Targeted Therapies and Chemotherapy

Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.

Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses the administration of targeted therapies and chemotherapy for patients with non-small cell lung cancer (NSCLC).

Scagliotti believes that chemotherapy and targeted therapies can be used together, when given sequentially. As an example, patents that develop an acquired mutation in T790M after receiving an EGFR targeted therapy may be more sensitive to chemotherapy. Additionally, trials have shown that patients with ALK translocations demonstrate lower TS RNA levels, denoting sensitivity to pemetrexed.

Overall, targeted therapies and chemotherapy should not be used concomitantly, Scagliotti believes. But in the near future, for a molecularly defined patient population, targeted therapies could be combined in a sequential fashion with cytotoxic chemotherapies for patients with NSCLC.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine